Key points are not available for this paper at this time.
Tumor burden reduction was noted in a proportion of patients who received TBP with nivolumab in CheckMate 141. Additional research is warranted to identify factors predictive of a TBP benefit in this population.
Haddad et al. (2019) studied this question.